# Clinical Importance of Treating Iron Overload in Sickle Cell Disease

> **NCT00981370** · PHASE3 · TERMINATED · sponsor: **Children's Hospital Los Angeles** · enrollment: 1 (actual)

## Conditions studied

- Anemia, Sickle Cell
- Transfusion Hemosiderosis

## Interventions

- **DRUG:** deferasirox

## Key facts

- **NCT ID:** NCT00981370
- **Lead sponsor:** Children's Hospital Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2010-10
- **Final completion:** 2010-12
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** 1 consented patient never started on study drug, lost to follow up
- **Last updated:** 2017-02-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00981370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00981370, "Clinical Importance of Treating Iron Overload in Sickle Cell Disease". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00981370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*